Subscribe to RSS
DOI: 10.1055/a-1527-1197
lncRNA MALAT-1 Predicts Prognosis of Patients with Systemic Lupus Erythematosus
lncRNA MALAT-1 sagt die Prognose der Patienten mit systemischem Lupus erythematodes vorausAbstract
Objective To evaluate the association of MALAT-1 and the prognosis of patients with systemic lupus erythematosus (SLE).
Materials and Methods A total of 87 SLE patients and 50 healthy controls were recruited. The expression levels of MALAT-1 were measured by quantitative PCR at baseline. Multivariate Cox regression analysis was performed to assess the association of MALAT-1 levels with survival after adjusting for potential confounding factors.
Results The MALAT-1 levels in patients with SLE were significantly higher compared with healthy controls (p<0.01). The 10-year survival of patients with a higher MALAT-1 level was significantly lower than that of patients with a lower MALAT-1 level (HR=5.54; 95% CI: 1.49–20.55; p=0.01). Multivariate Cox regression indicated that the MALAT-1 level was significantly associated with a risk of mortality (HR=10.02, 95% CI: 1.14–88.14, p=0.04).
Conclusion The expression levels of MALAT-1 may be a promising biomarker for evaluating the prognosis of SLE patients.
Zusammenfassung
Ziel Die Assoziation von MALAT-1 und der Prognose der Patienten mit systemischem Lupus erythematodes (SLE) zu bewerten.
Material und Methoden Insgesamt wurden 87 SLE-Patienten und 50 gesunde Kontrollpersonen rekrutiert. Die Expressionsniveaus von MALAT-1 wurden zu Beginn der Studie durch quantitative PCR gemessen. Eine multivariate Cox-Regressionsanalyse wurde durchgeführt, um die Assoziation der MALAT-1-Spiegel mit dem Überleben nach Bereinigung um mögliche Störfaktoren zu bewerten.
Ergebnisse Die MALAT-1-Spiegel bei Patienten mit SLE waren im Vergleich zu gesunden Kontrollen signifikant höher (P<0,01). Das 10-Jahres-Überleben von Patienten mit einem höheren MALAT-1-Spiegel war signifikant niedriger als bei Patienten mit einem niedrigeren MALAT-1-Spiegel (HR=5,54; 95% CI: 1,49–20,55; P =0,01). Die multivariate Cox-Regression zeigte, dass der MALAT-1-Spiegel signifikant mit einem Mortalitätsrisiko assoziiert war (HR=10,02, 95% CI: 1,14–88,14, P=0,04).
Schlussfolgerung Die Expressionsniveaus des MALAT-1-Niveaus könnten ein vielversprechender Biomarker für die Bewertung der Prognose von SLE-Patienten sein.
Publication History
Article published online:
03 August 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Grammatikos AP, Kyttaris VC, Kis-Toth K. et al. A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clin Immunol 2014; 150: 192-200. DOI: 10.1016/j.clim.2013.12.002.
- 2 Kang SC, Hwang SJ, Chang YS. et al. Characteristics of comorbidities and costs among patients who died from systemic lupus erythematosus in Taiwan. Arch Med Sci 2012; 8: 690-696. DOI: 10.5114/aoms.2012.30293.
- 3 Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 2019; 96: 1-13. DOI: 10.1016/j.jaut.2018.11.001.
- 4 Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus 2010; 19: 1365-1373. DOI: 10.1177/0961203310374305.
- 5 Zou YF, Feng CC, Zhu JM. et al. Prevalence of systemic lupus erythematosus and risk factors in rural areas of Anhui Province. Rheumatol Int 2014; 34: 347-356. DOI: 10.1007/s00296-013-2902-1.
- 6 Du Y, Sun F, Zhou M. et al. The expression and clinical significance of different forms of LILRA3 in systemic lupus erythematosus. Clin Rheumatol 2019; 38: 3099-3107. DOI: 10.1007/s10067-019-04624-z.
- 7 Kapranov P, Cheng J, Dike S. et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007; 316: 1484-1488. DOI: 10.1126/science.1138341.
- 8 Patel SA, DeMichele A. Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data. Curr Oncol Rep 2017; 19: 56. DOI: 10.1007/s11912-017-0613-6.
- 9 Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-914. DOI: 10.1016/j.molcel.2011.08.018.
- 10 Spizzo R, Almeida MI, Colombatti A. et al. Long non-coding RNAs and cancer: a new frontier of translational research?. Oncogene 2012; 31: 4577-4587. DOI: 10.1038/onc.2011.621.
- 11 Knauss JL, Sun T. Regulatory mechanisms of long noncoding RNAs in vertebrate central nervous system development and function. Neuroscience 2013; 235: 200-214. DOI: 10.1016/j.neuroscience.2013.01.022.
- 12 Schonrock N, Harvey RP, Mattick JS. Long noncoding RNAs in cardiac development and pathophysiology. Circ Res 2012; 111: 1349-1362. DOI: 10.1161/CIRCRESAHA.112.268953.
- 13 Ji P, Diederichs S, Wang W. et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22: 8031-8041 DOI: 10.1038/sj.onc.1206928.
- 14 Eissmann M, Gutschner T, Hammerle M. et al. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol 2012; 9: 1076-1087. DOI: 10.4161/rna.21089.
- 15 Kong X, Wang J, Cao Y. et al. The long noncoding RNA MALAT-1 functions as a competing endogenous RNA to regulate MSL2 expression by sponging miR-338-3p in myasthenia gravis. J Cell Biochem 2019; 120: 5542-5550. DOI: 10.1002/jcb.27838.
- 16 Cardamone G, Paraboschi EM, Solda G. et al. Not only cancer: the long non-coding RNA MALAT1 affects the repertoire of alternatively spliced transcripts and circular RNAs in multiple sclerosis. Hum Mol Genet 2019; 28: 1414-1428. DOI: 10.1093/hmg/ddy438.
- 17 Yang H, Liang N, Wang M. et al. Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus. Oncotarget 2017; 8: 77400-77406 DOI: 10.18632/oncotarget.20490.
- 18 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725. DOI: 10.1002/art.1780400928.
- 19 Gheita TA, Abdel Rehim DM, Kenawy SA. et al. Clinical significance of matrix metalloproteinase-3 in systemic lupus erythematosus patients: a potential biomarker for disease activity and damage. Acta Reumatol Port 2015; 40: 145-149
- 20 Wang Z, Li M, Wang Y. et al. Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. Lupus 2018; 27: 864-869. DOI: 10.1177/0961203317751852.
- 21 Mak A, Cheung MW, Chiew HJ. et al. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41: 830-839. DOI: 10.1016/j.semarthrit.2011.11.002.
- 22 Ge J, Jin Z, Feng X. et al. Creatinine clearance rate predicts prognosis of patients with systemic lupus erythematosus: a large retrospective cohort study. Clin Rheumatol 2020; DOI: 10.1007/s10067-020-05485-7.
- 23 Masoumi F, Ghorbani S, Talebi F. et al. Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis. J Neuroimmunol 2019; 328: 50-59. DOI: 10.1016/j.jneuroim.2018.11.013.
- 24 Alarcon GS. Multiethnic lupus cohorts: what have they taught us?. Reumatol Clin 2011; 7: 3-6. DOI: 10.1016/j.reuma.2010.11.001.
- 25 Fouada NA, Shaker OG, Mohamed EA. et al. Diagnostic potential of metastasis-associated-lung-adenocarcinoma-transcript-1 (MALAT-1) and TNFα and hnRNPL related immunoregulatory long non-coding RNA (THRIL) in systemic lupus erythematosus patients: Relation to disease activity. The Egyptian Rheumatologist 2019; 41: 197-201
- 26 Fors Nieves CE, Izmirly PM. Mortality in Systemic Lupus Erythematosus: an Updated Review. Curr Rheumatol Rep 2016; 18: 21. DOI: 10.1007/s11926-016-0571-2.
- 27 Feng X, Pan W, Liu L. et al. Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort. PLoS One 2016; 11: e0168619. DOI: 10.1371/journal.pone.0168619.
- 28 Tedeschi SK, Bermas B, Costenbader KH. Sexual disparities in the incidence and course of SLE and RA. Clin Immunol 2013; 149: 211-218. DOI: 10.1016/j.clim.2013.03.003.